Other studies have reached the same conclusion, showing that targeted therapy is significantly more effective than conventional regimens in the postoperative adjuvant treatment of patients with early-stage lung adenocarcinoma with EGFR gene mutations [22, 23]. The gene discussed is EGFR; the disease is lung adenocarcinoma.